摘要
目的:研究开心解郁丸治疗抑郁症的疗效及机理。方法:采用慢性不可预见性温和应激叠加孤养大鼠抑郁模型研究开心解郁丸对糖水偏嗜、水迷宫等抑郁样行为及神经元可塑性相关基因糖原合成酶激酶-3β(GSK-3β)、环磷腺苷反应元件结合蛋白(CREB)、5-羟色胺受体2C(HTR2C)、血管内皮生长因子(VEGF)的调控作用。结果:大鼠抑郁模型中,开心解郁丸可显著增加糖水消耗百分比,一定程度上增加水迷宫逃避潜伏期,明显降低神经元可塑性相关基因GSK-3β和HTR2C m RNA、明显升高CREB和VEGF m RNA。结论:开心解郁丸对抑郁大鼠有一定的抗抑郁作用,可能与调节神经元可塑性相关基因GSK-3β、CREB、HTR2C和VEGF有关。
This article was aimed to depression. The depression model rats investigate the function and mechanism of Kai-Xin Jie-Yu (KXJY) pill on were established by chronic unpredictable mild stress and separation. The sucrose preference test and Morris water maze (MWM) were performed. The regulation effects of neural plasticity-related genes including glycogen synthase kinase-3β (GSK-3β), cAMP-response element binding protein (CREB), 5-hydroxytryptamine 2C receptors (HTR2C), and vascular endothelial growth factor (VEGF) were determined. The results showed that among depression model rats, KXJY pill significantly increased the sucrose preference and the escape latency of MWM in a certain extent. The neural plasticity-related genes including GSK-3β and HTR2C mRNA were decreased significantly, whereas CREB and VEGF mRNA were increased significantly with the treatment of KXJY pill. It was concluded that KXJY pill had the function of reducing depression-like behavior, which might be mediated by the regulation of GSK-3β, CREB, HTR2C and VEGF.
出处
《世界科学技术-中医药现代化》
CSCD
2017年第8期1351-1354,共4页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
国家自然科学基金项目(81573790):基于lncRNA-miRNA网络对神经血管单元稳态调控探讨益气开郁中药抗抑郁机制
负责人:黄世敬
国家自然科学基金项目(81603443):开心解郁丸通过长链非编码RNA调控JAK-STAT通路治疗血管性抑郁的研究
负责人:潘菊华
北京市科技计划"十病十药"研发专项(Z161100001816013):开心解郁颗粒治疗血管性抑郁症的成药性研究
负责人:黄世敬
关键词
开心解郁丸
抑郁
大鼠
神经元可塑性
Kai-Xin Jie- Yu pill, depression, rat, neural plasticity